Tulsa, OK, November 20, 2013 --(PR.com
)-- Emerge Diagnostics, LLC. announced today the appointment of Robert Thompson as its new CEO. “It’s an exciting time here at Emerge! Robert is well suited to take the helm and lead Emerge into the future and we’re thrilled to have him onboard,” stated outgoing CEO and Chairman of the Board, Jerry Wilkins. Mr Thompson stated, “I am very excited to pursue the major growth opportunities at Emerge, as we bring evidence based medicine to the diagnosis and treatment of soft tissue injuries. The EmergeElectrodiagnostic Functional Assessment technology, which recently received its wireless device clearance from the FDA, has the potential to revolutionize the field.”
Mr. Thompson was previously CEO of eScreen, Inc., a high-growth provider of employment related diagnostics and medical services. Under Thompson’s leadership at eScreen, revenues grew from $28 million in 2002 to over $160 million in 2012. At eScreen, Thompson negotiated two rounds of equity investment, bringing in both VintageCapital, LLC and the Carlyle Group. In April of 2012, eScreen was sold to Alere, Inc. for $270 million plus contingent considerations.
Prior to eScreen; Mr. Thompson was CEO of Orasure Technologies, a publicly traded diagnostics company, and CFO and COO at LabOne, a publicly traded diagnostic laboratory and services provider. Mr. Thompson is a graduate of The Wharton School at the University of Pennsylvania, and received his MBA from Harvard Business School.
Jerry Wilkins will continue with the company in the role as President and Chief Operating Officer.
About Emerge Diagnostics:
Emerge Diagnostics is the provider of the Electrodiagnostic Functional Assessment, EFA and EFA-STM©. The EFA-Soft Tissue Management (EFA-STM) program is a bookend workplace injury management solution, enabled by the advanced diagnostic insight provided by the company's EFA technology. For more about Emerge Diagnostics, please visit our website at www.emergedx.com.